First OAC prescription between January 2013 and March 2016 with at least one year of baseline enrollment prior to index date (n = 98,093)

Excluded
- Patients without AF or with atrial flutter diagnosis in the same or preceding quarter of the index date (n = 40,773)
- Age < 18 (n = 163)
- Patients with dialysis/valvular disorder/thrombosis/pregnancy in the four quarters before or at index date (n = 4690)
- Prescriptions of OAC for any other indication in the four quarters before or at index date (n = 810)
- Patients initiating with more than one OAC at the index date (n = 51)

(n = 57,320)

Excluded
- Age < 18 (n = 163)
- Patients with dialysis/valvular disorder/thrombosis/pregnancy in the four quarters before or at index date (n = 4690)
- Prescriptions of OAC for any other indication in the four quarters before or at index date (n = 810)
- Patients initiating with more than one OAC at the index date (n = 51)

Final study population (n = 51,606)

All NOACs 30,138 (58.4%)
- Apixaban 8832 (17.1%)
- Dabigatran 3973 (7.7%)
- Rivaroxaban 17,333 (33.6%)

VKA 21,468 (41.6%)
- Switch to VKA 1573 (5.2%)
- Switch to apixaban 798 (2.6%)
- Switch to dabigatran 607 (2.0%)
- Switch to rivaroxaban 1366 (6.4%)
- Discontinued 6796 (25.2%)
- Continued on VKA 15,288 (71.2%)

Switch to apixaban 350 (4.0%)
- Switch to dabigatran 70 (0.8%)
- Switch to rivaroxaban 193 (2.2%)
- Discontinued 1760 (19.9%)
- Continued on apixaban 6459 (73.1%)

Switch to VKA 251 (6.3%)
- Switch to apixaban 172 (4.3%)
- Switch to rivaroxaban 229 (5.8%)
- Discontinued 1000 (25.2%)
- Continued on apixaban 2321 (58.4%)

Switch to VKA 972 (5.6%)
- Switch to apixaban 626 (3.6%)
- Switch to dabigatran 207 (1.2%)
- Discontinued 4248 (24.5%)
- Continued on rivaroxaban 11,280 (66.6%)

All NOACs 30,138 (58.4%)
- Switch to apixaban 76 (0.8%)
- Switch to dabigatran 70 (0.8%)
- Switch to rivaroxaban 193 (2.2%)
- Discontinued 1000 (3.3%)
- Continued on NOAC 20,060 (66.6%)

Switch to VKA 350 (4.0%)
- Switch to apixaban 251 (6.3%)
- Switch to dabigatran 172 (4.3%)
- Switch to rivaroxaban 229 (5.8%)
- Discontinued 1000 (25.2%)
- Continued on VKA 15,288 (71.2%)

Switch to apixaban 291 (1.3%)
- Switch to dabigatran 304 (1.0%)
- Switch to rivaroxaban 1366 (6.4%)
- Discontinued 3797 (17.7%)
- Continued on NOAC 20,060 (66.6%)

Thrombosis and Haemostasis

Changes in Oral Anticoagulation Therapy
Hohnloser et al..